<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Milan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16362647</article-id><article-id pub-id-type="pmc">3452313</article-id><article-id pub-id-type="publisher-id">156</article-id><article-id pub-id-type="doi">10.1007/s10194-005-0156-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original</subject></subj-group></article-categories><title-group><article-title>Managing migraine headaches experienced by patients who self–report with menstrually related migraine: a prospective, placebo–controlled study with oral sumatriptan</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Dowson</surname><given-names>A. J.</given-names></name><address><phone>+44-1428-712546</phone><fax>+44-1428-712546</fax><email>andydowson@psim-limited.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Massiou</surname><given-names>H.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Aurora</surname><given-names>
S. K.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>The King’s Headache Service, King’s College Hospital, Denmark Hill, London SE5 9RS, UK </aff><aff id="Aff2"><label>2</label>Department of Neurology, Hospital Lariboisiere, Paris, France </aff><aff id="Aff3"><label>3</label>Swedish Headache Center and
Neurosciences Institute, Seattle, WA USA </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>4</month><year>2005</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2005</year></pub-date><volume>6</volume><issue>2</issue><fpage>81</fpage><lpage>87</lpage><history><date date-type="received"><day>25</day><month>10</month><year>2004</year></date><date date-type="accepted"><day>16</day><month>2</month><year>2005</year></date></history><permissions><copyright-statement>© Springer-Verlag
Italia 2005</copyright-statement></permissions><abstract id="Abs1"><p><offsets xml_i="2635" xml_f="3645" txt_i="11" txt_f="1021">The objective was to evaluate the efficacy and tolerability of oral sumatriptan (100 mg) in patients who self–reported with menstrually related migraine. A prospective, multicentre, randomised, double–blind, placebocontrolled, two–group crossover study was carried out in 20 UK primary and secondary care surgeries. Of 115 patients with a self–reported history of menstrually related migraine that entered the study, 93 patients completed it. Patients treated all migraine attacks for 2 months with sumatriptan (100 mg) and for 2 months with placebo. The primary endpoint was the proportion of patients reporting headache relief at 4 hours for the first treated attack. Only 11% of patients fulfilled the protocol definition of menstrually related migraine. Patients reported a variable pattern of migraine attacks occurring inside and outside the menstrual window. For the first attack, significantly more patients receiving sumatriptan than placebo reported headache relief for attacks occurring inside (67% </offsets><italic><offsets xml_i="3653" xml_f="3655" txt_i="1021" txt_f="1023">vs</offsets></italic><offsets xml_i="3664" xml_f="3671" txt_i="1023" txt_f="1030">. 33%, </offsets><italic><offsets xml_i="3679" xml_f="3680" txt_i="1030" txt_f="1031">p</offsets></italic><offsets xml_i="3689" xml_f="3714" txt_i="1031" txt_f="1056">=0.007) and outside (79% </offsets><italic><offsets xml_i="3722" xml_f="3724" txt_i="1056" txt_f="1058">vs</offsets></italic><offsets xml_i="3733" xml_f="3740" txt_i="1058" txt_f="1065">. 31%, </offsets><italic><offsets xml_i="3748" xml_f="3749" txt_i="1065" txt_f="1066">p</offsets></italic><offsets xml_i="3758" xml_f="3963" txt_i="1066" txt_f="1268">&lt;0.001) the menstrual period. Sumatriptan was generally well tolerated. Oral sumatriptan (100 mg) is an effective and well tolerated acute treatment for patients who report menstrually related migraine.</offsets></p></abstract><kwd-group xml:lang="en"><title>Key words</title><kwd>Headache spectrum</kwd><kwd>Menstrual migraine</kwd><kwd>Sumatriptan</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Springer-Verlag
Italia 2005</meta-value></custom-meta></custom-meta-group></article-meta></front></article>